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Malignant peripheral nerve sheath tumors (MPNSTs)
are soft tissue sarcomas that arise in connective
tissue surrounding peripheral nerves. They occur
sporadically in a subset of patients with neurofibro-
matosis type 1 (NF1). MPNSTs are highly aggressive,
therapeutically resistant, and typically fatal. Using
comparative transcriptome analysis, we identified
CXCR4, a G-protein-coupled receptor, as highly ex-
pressed in mouse models of NF1-deficient MPNSTs,
but not in nontransformed precursor cells. The che-
mokine receptor CXCR4 and its ligand, CXCL12,
promote MPNST growth by stimulating cyclin D1
expression and cell-cycle progression through PI3-
kinase (PI3K) and b-catenin signaling. Suppression
of CXCR4 activity either by shRNA or pharmacolog-
ical inhibitiondecreasesMPNSTcell growth in culture
and inhibits tumorigenesis in allografts and in sponta-
neous genetic mouse models of MPNST. We further
demonstrate conservation of these activated molec-
ular pathways in human MPNSTs. Our findings indi-
cate a role for CXCR4 in NF1-associated MPNST
development and identify a therapeutic target.
INTRODUCTION
The tumor predisposition disorder von Recklinghausen’s neuro-
fibromatosis type I (NF1) is one of the most common genetic
disorders of the nervous system, affecting one in 3,500 individ-
uals worldwide (Zhu and Parada, 2001). A cardinal feature of
NF1 is the growth of benign tumors called neurofibromas, cate-
gorized into plexiform and dermal subtypes (Le and Parada,
2007). Plexiform neurofibromas can undergo malignant transfor-mation into neurofibrosarcomas, known as malignant peripheral
nerve sheath tumors (MPNSTs), which represent a major source
of morbidity for NF1 patients (Ferner, 2007). Despite continued
progress in understanding NF1 biology, MPNST treatment
remains limited to surgery, and prognosis remains unchanged
(Tonsgard, 2006).
The development of murine models has provided an opportu-
nity to gain insight into NF1-deficient tumor natural history
(Cichowski et al., 1999; Joseph et al., 2008; Vogel et al., 1999;
Zheng et al., 2008; Zhu et al., 2002). NF1 and TP53, or CDKN2a,
are the most frequently mutated cancer-related genes in human
MPNSTs (Mantripragada et al., 2008; Rubin and Gutmann,
2005). Our genetically engineeredmousemodels (GEMMs) reca-
pitulate tumors that arise in NF1 patients, and we and others
have shown that genetic ablation of the NF1 and p53 tumor
suppressors results in spontaneous development of MPNSTs
(Cichowski et al., 1999; Vogel et al., 1999). Benign and malignant
Nf1-deficient tumors can also be induced by subcutaneous
implantation of Nf1- or Nf1;p53-deficient skin-derived precur-
sor (SKPs), respectively, and are histologically indistinguishable
from human counterparts (Le et al., 2009); L.Q.L., T. Shipman,
and L.F.P., unpublished data).
Here, we examine the chemokine receptor CXCR4, which we
find enriched in Nf1-deficient cells and particularly in Nf1-defi-
cient MPNSTs. Expression of CXCR4 and its ligand, CXCL12,
has been reported in solid tumors, (Kijima et al., 2002; Koshiba
et al., 2000; Laverdiere et al., 2005; Mu¨ller et al., 2001; Oh et al.,
2001; Righi et al., 2011; Schrader et al., 2002; Sehgal et al.,
1998; Sengupta et al., 2012; Taichman et al., 2002; Zeelenberg
et al., 2003; Zhou et al., 2002) as well as non-Hodgkin’s
lymphoma (Bertolini et al., 2002) and chronic lymphocytic
leukemia (Burger et al., 1999). Clinical data indicate that high
CXCR4 correlates with poor clinical outcome (Bian et al.,
2007; Li et al., 2004; Wang et al., 2008). The proposed paracrine
roles for CXCR4/CXCL12 in a variety of tumorigenic processes
include cell growth (Schrader et al., 2002; Zhou et al., 2002),Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc. 1077
metastasis (Li et al., 2004), and angiogenesis (Sengupta et al.,
2012).
A potential role for CXCR4 in sarcoma pathogenesis has not
been examined. Here, we provide evidence that the CXCR4/
CXCL12 axis is essential for MPNST tumor progression. Specif-
ically, the autocrine activation of CXCR4 by CXCL12 triggers
intracellular PI3-kinase (PI3K) and b-catenin signals to promote
G1 to S phase transition in MPNST cells. The CXCR4 antagonist,
AMD3100, has growth-inhibitory effects on primary cultured
mouse and human MPNST cells, tumor allografts, and sponta-
neous GEMMs. Moreover, analysis of human primary and
cultured MPNST cells, as well as human tissue microarray anal-
ysis, reveals conserved pathway activation. Thus, CXCR4 inhibi-
tion may represent a therapeutic strategy to treat MPNST.
RESULTS
CXCR4 in Nf1-Deficient MPNST Tumors
Previously, we demonstrated that Nf1-deficient SKPs can give
rise to either dermal or plexiform neurofibromas depending on
their local microenvironment (dermis versus sciatic nerve) (Le
et al., 2009). In addition, dual mutation of the Nf1 and p53 tumor
suppressors in these cells results in MPNSTs that exhibit cellular
and molecular features of human MPNSTs (L.Q.L., T. Shipman,
and L.F.P., unpublished data). These tumors are indistinguish-
able from a spontaneous MPNST GEMM also based on loss of
Nf1 and p53 (cisNP; Cichowski et al., 1999; Vogel et al., 1999).
To gain insight into the molecular and cellular mechanisms
underlying development of Nf1-deficient MPNSTs, we used
microarray analysis to compare the transcriptomes of MPNSTs
with those of normal SKPs (WT), as well as pretumorigenic
SKPs with either Nf1 deletion (Nf/) or Nf1 and p53 (NP/)
deletion, as shown in Figure 1A. The comparative array data pre-
sented a complex picture of up- and downregulated transcripts
for diverse genes (data not shown). However, our attention was
drawn to the elevated expression of the chemokine receptor
CXCR4 that exhibited a 3-fold elevation in both pretumor cell
types (Nf/; NP/) and a 12-fold increase in the malignant
form of SKP MPNST (SMPNST). Quantitative RT-PCR and
western blot analysis (Figures 1B and 1C) confirmed these array
data. We also measured low CXCR4 levels in Schwann cells,
which belong to the embryonic lineage of origin of Nf1-deficient
tumors (Le et al., 2011; Serra et al., 2000; Zhu et al., 2002), and
high levels in tumor cells from the spontaneous cisNP mouse
model of MPNST by western blot (Figure S1A available online;
[Vogel et al., 1999]) and immunohistochemistry (IHC). We further
performed IHC on tumor samples from the SMPNST-allograft,
cisNP, and SMPNST-autograft models and a human MPNST
sample (Figures 1D and S1B). Together, these data confirmed
elevated CXCR4 protein in the different sources of Nf1-deficient
malignant tissues compared to controls and, further, provided
evidence that CXCR4 expression is sustained in human NF1-
associated MPNST.
CXCR4 Knockdown Impairs Cell Proliferation and
Attenuates Tumorigenesis
To evaluate the functional role of CXCR4 in MPNST pathogen-
esis, we used short hairpin RNA (shRNA) for knockdown in1078 Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc.SMPNST cells. Cells were infected with lentivirus containing
CXCR4 shRNA or a control scrambled shRNA (pLKO ctrl), and
stable cell lines were established using puromycin selection.
Two different shRNA sequences, targeting either the coding
region (pLKO-mCXCR4) or the 30 UTR (pLKO-mCXCR4-UTR)
reduced CXCR4 messenger RNA (mRNA) levels by 90%
(Figures S2A and S2B). To address whether CXCR4 influences
SMPNST cell metabolism, we measured ATP levels using a
luminescence assay and found that tumor cells with depleted
CXCR4 were less metabolically active. Introduction of exoge-
nous CXCR4 complementary DNA (cDNA) lacking the UTR
sequences (so that it is not targeted by the shRNA) re-estab-
lished CXCR4 protein levels and overcame the cell growth inhi-
bition (Figures 2A and S2B).
We turned to a doxycycline (dox)-inducible Mir30-based
shRNA system to enable acute knockdown of CXCR4. Using
this system, murine and human CXCR4 mRNA levels were
decreased to 25% and 10% of the origin level, respectively
(Figures S2C–S2F). In contrast, induction with dox had no effect
on CXCR4 expression in MPNST-Tripz-scrambled control cells
(Figures S2C–S2F). Similar to the pLKO knockdown results, we
observed cell growth arrest in CXCR4-depleted SMPNST and
human MPNST (S462) cells upon dox treatment (Figure 2B).
Together, these results confirm that CXCR4 plays a role in
murine- and human-derived MPNST cell proliferation.
We next investigated the growth properties of tumor cells
in vivo after CXCR4 knockdown. 104 or 105 pLKO-mCXCR4 or
pLKO-ctrl SMPNST cells were injected subcutaneously into
nudemice andmonitored for tumor growth (SMPNST-allografts).
The mice were sacrificed and tumors were dissected 1 month
after injection (Figure S2G). Quantification of tumor size and
weight showed that MPNST cells with CXCR4 knockdown
generated smaller tumors than control cells (Figure S2H), and
additionally, time to tumor appearance was significantly in-
creased (Figure S2I). We also analyzed cell proliferation in
excised tumors and found the average percentage of Ki67-
positive, proliferating cells was 24.2% ± 6.5% in CXCR4-
depleted MPNSTs versus 67.6% ± 5.1% in controls (Figures
S2J and S2K).
Similar results were obtained when the inducible shRNA
tumor cells were implanted and subjected to dox-mediated
CXCR4 knockdown after the tumor cells had successfully
seeded in the allograft. This approach eliminated the possibility
that CXCR4 knockdown in culture impeded subsequent tumor
cell implantation. 104 or 105 MPNST-Tripz-CXCR4 cells were in-
jected subcutaneously into nude mice, and one group received
dox (1 mg/ml) in the drinking water (Figure 2C). Compared to
controls, tumor appearance in the dox-treated group was de-
layed by 1 week, and tumor progression was impaired (Figures
2C and 2D). All mice were sacrificed on day 26, and tumors
were excised. Western blot analysis showed an 73.1% deple-
tion of CXCR4 protein in the tumors harvested from dox-treated
mice (Figure 2E). When 105 cells were injected, 6/6 control mice
bore tumors (759 ± 500 mm3 in size and 0.467 ± 0.226 g in
weight), and 5/6 dox-treated mice developed tumors that were
smaller both in size (199 ± 115 mm3) and weight (0.1 ± 0.08 g)
(Figures 2F and 2G). Notably, when 104 cells were injected, no
dox-treated mice developed tumors, whereas control group
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Figure 1. CXCR4 Is Overexpressed in
MPNSTs
(A) Schema of the microarray analyses.
(B) qRT-PCR analysis of CXCR4mRNA levels in WT,
Nf/, and NP/ (Nf/;p53/) SKPs, as well as
MPNST SKP model tumors and the cells derived
from the tumor.
(C) Western blot analysis of CXCR4 protein levels in
Nf/ and NP/ SKPs and SMPNST cancer cells.
(D) Quantification of CXCR4-positive cells in tumor
tissues from different mouse models of MPNST and
an MPNST from an NF1 patient (SMPNST =
SMPNST autograft; athymic model = SMPNST
allograft).
All statistics represent mean ±SD. See also
Figure S1.
Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc. 1079
A B
C D
E
F G
Figure 2. Knockdown of CXCR4 Expression
in MPNST Cells Decreased Proliferation
In Vitro and Tumorigenesis In Vivo
(A and B) ATP luminescence assays were used to
measure growth of indicated cells.
(C and D) Representative pictures of the tumors
from nude mice injected with SMPNST-Tripz-
mCXCR4 cells. Mice 1–6: without Dox treatment;
mice 7–12: Dox treatment.
(E) CXCR4 protein level is downregulated in dox-
treated MPNSTs.
(F) Kinetic curve of tumor growth as measured by
tumor volume.
(G) Quantification of tumor weight.
All statistics represent mean ±SD. See also
Figure S2.mice developed tumors (Figure 2D). Thus, both chronic and
acute suppression of CXCR4 in vivo substantially decreased
the tumorigenic capacity of MPNST cells.
CXCR4 Depletion Alters the MPNST Cell Cycle
We investigated possiblemechanisms of CXCR4 function in pro-
moting MPNST progression. shRNA depletion caused growth
arrest of SMPNSTs (Figure 2) rather than apoptosis (Figures1080 Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc.S3A and S3B) or senescence (Figures
S3C and S3D). Bromodeoxyuridine
(BrdU) incorporation and fluorescence-
activated cell sorting (FACS) analysis
showed significant reduction in BrdU
incorporation in CXCR4-depleted cells
(57.2% ± 3.6% versus 21.8% ± 2.6%;
Figure 3A). When CXCR4 protein level
was restored, the percentage of BrdU-
positive cells was also restored to that
of CXCR4-WT cells (Figure 3A). Addi-
tional cell-cycle analysis revealed that
the percentage of cells in G1 phase was
60% in CXCR4-depleted SMPNST cells
versus 25% in CXCR4-WT cells; by
contrast, the number of cells in G2/M
phase was only slightly changed (Figures
3B and S3E). These data suggest that
CXCR4-depleted MPNST cells undergo
G1/S arrest. We also performed BrdU
incorporation studies in vivo. Tumor-
bearing mice were injected with BrdU
3 hr before sacrifice. BrdU IHC revealed
42% ± 11% BrdU-positive cells in the
tumor samples from mice injected with
control SMPNST cells. In contrast, the
BrdU-positive cell number decreased
to 15% ± 5% in the tumor samples
from mice injected with CXCR4-depleted
SMPNST cells (Figures 3C and 3D).
Similar to the MPNST cell culture results,
there was no obvious apoptosis in either
tumor group (Figures S3F and S3G). Insummary, knockdown of CXCR4 expression, in culture and
in vivo, led to cell-cycle arrest manifested by reduced S phase
and BrdU incorporation, rather than cell death or senescence.
Cyclin D1 Expression Is Regulated by CXCR4
We next investigated whether CXCR4 perturbation impacts the
expression of cell-cycle-regulatory genes (Johnson and Walker,
1999; Lee and Yang, 2003; Obaya and Sedivy, 2002). Although
quantitative RT-PCR (qRT-PCR) analysis indicated that ex-
pression of most genes examined was unchanged in CXCR4-
depleted SMPNST cells and tumors, cyclin D1 mRNA levels
decreased 70% (Figures 3E and S3H). A slight reduction in
CDK4/6 and cyclin E mRNA levels was also observed (Figures
3E andS3H). Quantification of western blots confirmed the cyclin
D1 protein level decrease in CXCR4-depleted MPNST cells and
tumors (SMPNST allografts) (Figures 3F and S3I). Both cyclin D1
mRNA and protein levels were fully restored in CXCR4-depleted
MPNST cells with exogenous CXCR4 expression (Figures 3E
and 3F). Moreover, reintroduction of cyclin D1 cDNA restored
protein levels and counteracted the CXCR4 depletion effect,
allowing cells to resume progression through the cell cycle
(Figures 3G and 3H). These data demonstrate that, in SMPNST
cells, cell-cycle progression mediated by cyclin D1 is dependent
on CXCR4 function.
CXCR4 Activates the AKT/GSK-3b/b-Catenin Network
Signaling pathways known to regulate cyclin D1 include the
NFkB, Ras, ERK, Wnt/b-catenin, and JAK/STAT3 pathways
(Sherr, 1995). To determine whether any of these candidate
pathways mediate CXCR4 regulation of cyclin D1 in neurofibro-
sarcomas, fractionated nuclear and cytoplasmic extracts of
SMPNST cells were immunoblotted with the indicated anti-
bodies to examine changes following CXCR4 depletion. We
observed that both cyclin D1 and b-catenin levels decreased
76.4% and 77.3%, respectively, in the nuclear fraction of
CXCR4-depleted MPNST cells (Figure 4A). No changes were
seen in other pathways examined (Figure 4A). Transcriptional
activation assays using a luciferase reporter linked to the T cell
factor (TCF) promoter—a physiological target of b-catenin—
showed a 57% reduction in luciferase activity in CXCR4-
depleted SMPNST cells compared to controls, which is con-
sistent with the model that suppression of CXCR4 attenuated
b-catenin activity (Figure 4B). To test whether nuclear b-catenin
is required for cyclin D1 expression, we directly blocked TCF
function (Hoppler and Kavanagh, 2007). Expression of domi-
nant-negative TCF (dnTCF) dramatically decreased cyclin D1
mRNA and protein levels in CXCR4-WT-MPNST cells (Figures
4C and 4D), whereas overexpression of b-catenin in CXCR4-
depleted MPNST cells restored cyclin D1 expression (Figure 4E)
and, further, rescued the cell growth arrest caused by CXCR4
knockdown (Figure 4F). Functionally, downregulation of the
b-catenin pathway by dnTCF resulted in cell growth arrest in
MPNST cells (Figure S4A). We also examined tumors for b-cate-
nin expression. IHC on MPNST tumor tissues from SMPNSTs
(SMPNST allografts) (Figure S4B) and one human patient sample
(Figure S4C) showed robust nuclear immunoreactivity consistent
with activation of b-catenin signaling in these tumors.
The above data demonstrate a role for b-catenin downstream
of CXCR4 and upstream of TCF and cyclin D1 in stimulating
MPNST growth. b-catenin stabilization is required for its role as
a transcription factor. In the inactive state, b-catenin is destabi-
lized by phosphorylation at Ser33, Ser37, and Thr41 by GSK-3b
or at Ser45 by CK1a (Liu et al., 2002). Western blot analysis
showed that CXCR4 depletion increased b-catenin serine phos-
phorylation at sites 33/37, but not 45 (Figure 4G), suggesting that
CXCR4 suppression resulted in GSK-3b kinase activation. Wealso examined GSK-3b serine 9 inactivating phosphorylation
and observed a reduction in CXCR4-depleted MPNST cells
(Figure 4G). Thus, in MPNST, CXCR4 activity maintains GSK-
3b in the inactive state. GSK-3b is in turn a downstream element
of the PI3K/AKT signaling pathway (Cross et al., 1995) whose
kinase activity is inhibited by AKT-mediated phosphorylation
at Ser9 (Srivastava and Pandey, 1998). We reasoned that
the decreased phosphoSer9-GSK-3b level in CXCR4-depleted
MPNST cells might result from attenuated AKT kinase activity
and confirmed this by western blot analysis with pAKT (Ser473)
antibody (Figure 4G). We also found reduced levels of activated
b-catenin, pGSK-3b (Ser9), and pAKT (Ser473) in CXCR4-
depleted MPNST tumor samples compared to control tumors
(SMPNST allografts) (Figure 4H). These data support the model
that CXCR4 promotes MPNST growth by activating the PI3K/
AKT and the GSK-3b/b-catenin pathways. Previous in vitro
studies using human and murine MPNST cell lines, as well as
in vivo studies using the cisNP mouse model, demonstrated
that the mTOR pathway can regulate MPNST growth by
posttranscriptional regulation of cyclin D1 (Johannessen et al.,
2008). We observed modest reduction in phospho-mTOR upon
CXCR4 knockdown, but this was not accompanied by obvious
change in the levels of phosphorylated-S6 ribosomal protein
(Figure S4D). Collectively, our data indicate that CXCR4 regu-
lates the activity of b-catenin via the AKT/GSK-3b cascade,
which ultimately controls cyclin D1 transcription and protein
levels.
CXCL12 Activates CXCR4 in an Autocrine Loop
We sequenced CXCR4 cDNAs from two independent murine
MPNSTs, one derived from the SMPNST-allograft model and
one from the cisNP model, and found no missense or nonsense
mutations (data not shown). Moreover, CXCR4-activating muta-
tions have not been identified inMPNST cell lines or primary cells
derived from human patients (see below and Figure S5A). There-
fore, in these tumors, receptor activity must rely on the presence
of ligand—CXCL12. qPCR analysis showed that CXCL12 mRNA
was indeed elevated in pretumorigenic SKPs (NP/) and was
evenmore highly expressed in SMPNST tumor cells (Figure S5B).
To test the role of CXCL12 in MPNST cell growth, we treated
cultured MPNST cells with recombinant CXCL12 protein and
found that it promoted cell growth, generating a 1.5-fold increase
in cell number at a concentration of 10 ng/ml by day 6, when
compared to nontreated cells (Figure 5A). In contrast, cell
number decreased by 25% and 55% at days 3 and 6, respec-
tively, when cells were cultured with anti-CXCL12 antibody
compared to IgG or PBS control (Figure 5B). These data suggest
that CXCL12 is critical for MPNST cell proliferation. To verify the
autocrine source of CXCL12 ligand in theMPNST cell culture, we
performed an ELISA on themedium conditioned byMPNST cells
using an anti-CXCL12 antibody. We observed no detectable
CXCL12 protein in control media (with no cells) compared to
the conditioned media, indicating that the in vitro source of
CXCL12 protein is the MPNST cells (Figure 5C). Consistent
with the ELISA showing that conditioned media from CXCL12-
overexpressing MPNST cells (pBabe-CXCL12) and knockdown
cells (pLKO-CXCL12) contained elevated and reduced cytokine,
respectively (Figures 5C and S5C), CXCL12-overexpressingCell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc. 1081
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Figure 3. CXCR4 Alters the Cell Cycle in SMPNST Cells by Regulating Cyclin D1 Expression
SMPNST cells were incubated with BrdU for 30 min and then stained with propidium iodide.
(A and B) FACS analysis showed that CXCR4 depletion in SMPNST cells decreased the percentage of BrdU-positive cells (pLKO-mCXCR4 and pLKO-mCXCR4-
UTR compared to control pLKO-ctrl) (A) and altered the proportion of cells in G1 and S phases (B). Expression of CXCR4 in the knockdown cells (pLKO-mCXCR4-
UTR + Ub-CXCR4) restored the cells to the control state.
(legend continued on next page)
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cells had a significant growth advantage (Figure 5A), whereas
CXCL12 knockdown cells exhibited a significant reduction in
growth at days 3 and 6 (Figure 5D). Importantly, the cell growth
inhibition could be rescued by addition of CXCL12 protein
(Figure 5E). Therefore, MPNST cells synthesize and secrete
CXCL12 protein, causing increased cell growth that corre-
sponded with CXCL12 levels. To confirm that the effect of
CXCL12 on MPNST growth is dependent on CXCR4, we added
CXCL12 protein to cultured CXCR4-depleted MPNST cells. We
found no detectable change in cell proliferation after ligand stim-
ulation compared to control CXCR4-depleted MPNST cells (Fig-
ure 5E). Additionally, CXCL12 modulation in the presence of
receptor induced the same signaling pathway changes brought
about by CXCR4 modulation (Figure 5F). Taken together, these
data demonstrate that CXCL12, secreted by MPNST cells,
is sufficient to sustain autocrine activation of its receptor,
CXCR4, and triggers specific downstream signaling pathways,
leading to MPNST cell-cycle progression and proliferation.
Given the important roles of CXCR4/CXCL12 in tumor
angiogenesis, we also investigated whether CXCR4 depletion
in MPNST cells altered the microvasculature. Both control and
CXCR4-depleted tumors exhibit strong CD31 staining (Fig-
ure S5D) and similar vessel densities (Figure S5E), indicating
that the tumor growth arrest induced by CXCR4 depletion
is cell autonomous and not secondary to effects on the
microvasculature.
Pharmacological Inhibition of CXCR4 Arrests MPNST
Proliferation and Tumor Growth
We next tested a clinically validated, highly specific CXCR4
antagonist, AMD3100, in our system. We performed a dose-
response analysis of AMD3100 on primary murine MPNST cells
(SMPNSTs and cisNP), one primary human MPNST cell line,
three established human MPNST cell lines (S462; SNF02.2;
SNF96.2), and pretumor cells (Nf1;p53 null SKPs) (Figures 6A
and 6B). Four of six cell lineswere potently inhibited by low doses
of AMD3100 (IC50 values & 0.5 uM; Figure 6C). One human
MPNST cell line, SNF96.2, and the pretumor cells were less
sensitive (IC50 values of 1–10 uM; Figure 6C). Only one human
MPNST cell line, SNF02.2, showed no response, which is consis-
tent with its low endogenous CXCR4 levels relative to the other
MPNSTcells (Figure S6A). Of note, wewere unable to seed xeno-
graft tumors using SNF02.2 cells, suggesting that this cell line
has drifted significantly from the original tumor of derivation
(data not shown). In contrast, the cell viability of wild-type (WT)
Schwann cells and SKPs was unaffected by AMD3100 (Fig-
ure 6A). Inhibition of CXCR4 by AMD3100 also reduced cyclin
D1 levels via the AKT/GSK-3b/b-catenin pathway (Figure 6D).
To assess the therapeutic potential of AMD3100 in vivo, we
first tested subcutaneous allografts of primary SMPNSTs. Trans-(C) Paraffin sections of MPNSTs (harvested from SMPNST-allograft mice injecte
cells) were stained with antibody against BrdU and counterstained with hematox
(D) The percentage of SMPNST cells that were BrdU positive was determined fo
(E and F) Analysis of the expression levels of various cell-cycle genes/proteins in
(G) Cell growth curves of indicated cells as measured with an ATP luminescence
(H) CXCR4 and cyclin D1 protein levels were examined by western blotting in ind
Scale bar, 50 mm. All statistics represent mean ±SD (*p < 0.05 and **p < 0.01). Splant recipient animals with palpable tumors were treated with
AMD3100 and, after 3 weeks of treatment, were sacrificed for
analysis (Figure 6E). AMD3100 treatment potently suppressed
MPNST growth, resulting in reduced tumor size and weight
that was 38% and 42%, respectively, of the control group (Fig-
ure S6B). This was accompanied by commensurate reduction
in BrdU incorporation and Ki67 staining (Figures S6C and
S6D). Consistent with the in vitro data, AMD3100-treated tumors
showed decreased levels of cyclin D1, activated b-catenin,
phospho-AKT, and phospho-ser9-GSK-3b (Figure S6E).
To further validate the role of CXCR4 signaling in MPNST
growth and the potent cytostatic effect of AMD3100 on tumor
growth, we turned to a spontaneous endogenous GEMM. A
mouse strain in which null p53 and Nf1 alleles are configured in
cis on the same chromosome spontaneously develop MPNST
via loss of heterozygosity (LOH) of both tumor suppressor alleles
(cisNf/p53; Vogel et al., 1999). Although a majority of the sponta-
neous tumors are sarcomas, these cisNf/p53 mice are also
prone to other NF1-initiated tumors such as lymphomas and
gliomas, as well as to spontaneous p53-based tumors (Cichow-
ski et al., 1999; Vogel et al., 1999). Based on Kaplan-Meier curve
data that indicate spontaneous neurofibrosarcoma appearance
with 20% mortality at about 15 weeks of age and 70 percent
mortality at 25 weeks (n = 170; Vogel et al., 1999), we com-
menced the AMD3100 drug trial on cisNf/p53 mice at 16 weeks
of age. As shown in Figure 6F, at 2 months posttreatment
(24 weeks of age), 7/10 control mice (70%) had perished,
whereas, in the AMD3100 group, only 3/17 (18%) had perished.
All perished mice had large tumors, and histopathological anal-
ysis of the tumor tissues revealed that one mouse from the
control group and one from the experimental group had clear
evidence of a primary tumor of hematopoietic origin (Figures
S6F and S6G). Therefore, these mice were removed from
the study, resulting in a total of nine control mice and 16
AMD3100-treated mice (Figure 6G). Six out of nine control
mice developed lethal sarcomas. Five developed MPNST,
as evidenced by histopathological analysis and S100b and
GAP43 immunoreactivity (Figure 6F, C1, C2, and C5–C7; Fig-
ure S6H). A sixth control mouse died with a malignant triton
tumor (MTT), which is an NF1-associated sarcomatous tumor
having high myoglobin expression (Figure 6F, C4; and Fig-
ure S6I). All six tumors displayed CXCR4 expression (Figure 6F).
In contrast to the high mortality rate in the control group, at
2 months posttreatment, only two out of 16 mice from the
AMD3100 treatment group had perished with a solid tumor (Fig-
ure 6F, AMD1 and AMD3; Figure 6G). By histological analysis, we
determined that one of the tumors was a rhabdomyosarcoma
(RMS) with very low levels of CXCR4 expression (Figure 6F,
AMD3, and Figures S6J and S6K). The second treated mouse
developed a leiomyosarcoma (LMS) with CXCR4 expressiond with either control pLKO-ctrl or CXCR4-depleted pLKO-mCXCR4 SMPNST
ylin (blue).
r each tumor.
the indicated cells as measured by qPCR (E) and western blotting (F).
assay.
icated cells.
ee also Figure S3.
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Figure 4. CXCR4 Regulates Cyclin D1 Expression through the AKT/GSK-3b/b-Catenin Network
(A) Immunoblot of nuclear and cytoplasmic extracts from SMPNST cells with indicated antibodies.
(legend continued on next page)
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Figure 5. An Autocrine Mechanism Involving CXCL12 and CXCR4 Maintains Growth of MPNST Cells
(A and B) Growth curve of SMPNST cells treated with recombinant CXCL12 protein (A) or CXCL12/CXCR4 antibodies (B).
(C) ELISA to measure CXCL12 protein level in PBS, 5% fetal bovine serum (FBS) Dulbecco’s modified Eagle’s medium (DMEM) media, and conditioned media
from SMPNST cells or SMPNST cells expressing pBabe-CXCL12 (overexpression) or pLKO-CXCL12 (knockdown).
(D) Growth curve of control SMPNST cells (pLKO ctrl) and CXCL12-depleted SMPNST cells (pLKO-CXCL12).
(E) Growth curve of SMPNST cells, CXCR4-or CXCL12-depleted SMPNST cells, and CXCR4-or CXCL12-depleted SMPNST cells treated with recombinant
CXCL12 protein.
(F) Immunoblot of cell lysates from SMPNST cells and SMPNST cells expressing pLKO-CXCL12 or pBabe-CXCL12 with indicated antibodies.
All statistics represent mean ±SD (**p < 0.01). See also Figure S5.(Figure 6F, AMD1, and Figures S6L and S6M), suggesting that
this tumor escaped AMD3100 treatment. Whether this outlier
reflects failed drug delivery or, alternatively, an independent
mechanism of tumor promotion will require additional studies.
In summary, the allograft and genetic tumor model data
demonstrate that in vivo pharmacological blockade of CXCR4
can potently inhibit spontaneous MPNST tumor development
in a GEMM by blocking the same signaling pathways as ob-
served in primary tumor cultures.(B) Luciferase reporter assay to measure TCF activation in control SMPNST ce
mCXCR4-UTR), CXCR4-depleted SMPNST cells rescued by CXCR4 overexp
dominant-negative Tcf (pLKO-ctrl+Ub-dnTcf).
(C and D) ThemRNA and protein levels of cyclin D1 in SMPNST cells (ctrl) or SMPN
by western blotting (D).
(E) Immunoblot of cell lysates from SMPNST cells, CXCR4-depleted SMPNST
b-catenin with indicated antibodies (ABC: antibody against activated b-catenin).
(F) ATP luminescence assay to measure growth of indicated cells.
(G) Immunoblot of cell lysates from SMPNST cells and CXCR4-depleted SMPNS
(H) Graph showing fold change versus control of tumor tissue lysates from con
indicated antibodies.
All statistics represent mean ±SD (**p < 0.01). See also Figure S4.Conserved Signaling Pathway Activation in Human
MPNST
The above studies reflect analyses of genetic mouse models
extended to a single human tumor and primary MPNST
line plus three established human MPNST lines. To further
assess the relevance of our findings to human MPNST, we
examined CXCR4 in MPNSTs from patients with NF1. We
sequenced coding exons 1 and 2 (see Experimental Procedures)
of CXCR4 from a series of NF1-associated human MPNSTlls (pLKO-ctrl), CXCR4-depleted SMPNST cells (pLKO-mCXCR4 and pLKO-
ression (pLKO-mCXCR4-UTR+Ub-CXCR4), and SMPNST cells expressing
ST cells expressing dnTcf (dnTcf) were determined either by qPCR assay (C) or
cells, and CXCR4-depleted SMPNST cells ectopically expressing CXCR4 or
T cells with indicated antibodies.
trol SMPNSTs (ctrl) or SMPNSTs from CXCR4-depleted cells (mCXCR4) with
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Figure 6. AMD3100 Specifically Inhibits the Proliferation of SMPNST Cells and Suppresses the Growth of MPNSTs In Vivo
(A and B) Dose curve showing effect of AMD3100 on proliferation of murine (primary cells fromMPNST SKPmodel and cisNPmodel) and human (SNF 02.2, SNF
96.2, S462, and primary cells from a human NF1 patient) MPNST cells, pretumor SKP NP/ cells, and WT murine Schwann cells and SKPs.
(C) Experimentally derived AMD3100 IC50 values.
(D) Immunoblot with the indicated antibodies of cell lysates from murine cells in the absence or presence of AMD3100.
(E) Representative picture of the SMPNST-allograft tumors (from nude mice injected with SMPNST cells) during the treatment study with tumor histopathology
and immunohistochemistry.
(F) List of control (C-) and AMD3100-treated (AMD-) mice that died during the treatment study, with tumor histopathology and immunohistochemistry.
(G) Kaplan-Meier survival curve of mice in the AMD3100 treatment study (control group, n = 9; AMD3100-treated group, n = 16; p = 0.0017 by Mantel-Cox test).
Other statistics represent mean ±SD. See also Figure S6.samples and cell lines (Figure S5A), including S462, which
requires CXCR4 function for growth (Figure 6B); all CXCR4
coding regions analyzed had WT sequence (Figure S5A). Thus,
similar to the murine MPNSTs, human MPNST CXCR4 activity
must depend on ligand presence. We next examined CXCR4
protein expression using a human tissue microarray (TMA) that
included 17 plexiform neurofibromas (from NF1 patients har-
boring MPNSTs) and 73 MPNST samples (43 from NF1 patients
and 30 sporadic) (Ghadimi et al., 2012; Zou et al., 2009). The
data showed that 94% of neurofibromas and 98% of NF1-
deficient MPNSTs displayed CXCR4 immunoreactivity (Figures1086 Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc.7A and 7B), whereas only 66% of sporadic MPNSTs tissues
showed CXCR4 immunoreactivity. Similarly, 71% of neuro-
fibromas and 77% of NF1-associated MPNSTs exhibited
CXCR4 expression in >5% of tumor cells, as compared to
40% of sporadic MPNST tissues (Figure 7A). Spearman correla-
tion analysis showed a statistically significant difference in
CXCR4 intensity and distribution when comparing NF1-associ-
ated tumors to sporadic tumors (two-sided p = 0.0012 and
0.0008, respectively) (Figure 7B). We also assessed p-AKT,
b-catenin, and cyclin D1 expression and observed a direct con-
cordance between their levels and those of CXCR4 (p = 0.0198,
AB
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Figure 7. Analysis ofCXCR4Expressionand
Downstream Pathway Signaling Reveals
Conservation in Human MPNSTs
(A) Quantification of the intensity and distri-
bution of CXCR4 immunoreactive cells in all
MPNST TMAs.
(B) Schema of the CXCR4 distribution in TMAs.
Spearman correlation identified a statistically sig-
nificant difference between NF1-associated and
sporadic tumors (p = 0.0008).
(C) Spearman correlation coefficient analyses
between CXCR4, pAKT, b-catenin, and cyclin D1
in NF1-MPNST.
(D) Quantification of pAKT, b-catenin, and cyclin
D1 expression levels in MPNST-NF1 TMA and
categorization based on CXCR4 expression level.
Staining distribution of positively staining cells:
(0) = <5%, (1) = 5% – 30%, (2) >30%, and intensity:
(0) = negative, (1) = low, and (2) = intermediate to
high. Spearman’s correlation coefficient analyses
were used to determine the concordance between
CXCR4 expression and NF1 status and between
CXCR4 and other biomarkers.0.0028, and 1.93 3 104, respectively) (Figures 7C and 7D).
Thus, TMA data confirm that AKT/GSK-3b//b-catenin pathway
activation is conserved in human NF1-associated MPNSTs.
Extension of our functional data in murine and human MPNST
cells, coupled with the TMA studies, indicate that CXCR4 and
cyclin D1 are closely associated with clinical NF1-associated
pathogenesis.
DISCUSSION
We exploited the unique properties of GEMMs for NF1-associ-
ated MPNST that permitted isolation and direct comparison
with tumor cells of origin and precursor nontumor cells. The
progressively elevated expression of the chemokine receptor
CXCR4 along the increasingly tumorigenic series from premalig-Cell 152, 1077–1090, Fnant Nf1 null and Nf/p53 double null
tumor progenitors to Nf1 null benign
tumors (neurofibromas) and, finally, to
Nf/p53 double null MPNSTs drew our
attention and motivated the present
study.
CXCR4/CXCL12: An MPNST
Autocrine Loop
We also found increased CXCR4 expres-
sion in human NF1 patient tumor samples
and primary cells. CXCR4 is commonly
found in human and experimental murine
cancers. Protumorigenic paracrine func-
tions attributed to this G-protein-coupled
receptor/ligand include cell homing,
migration, and induction of neovasculari-
zation (Li et al., 2004; Sengupta et al.,
2012; Singh et al., 2004). In the present
study, we identify an autocrine loop incells that sustains activated CXCR4. MPNST cells with CXCR4
depletion exhibit proliferative arrest rather than cell death, with
fewer cells in S phase. Consistent with this, we found that the
G1/S phase transition protein cyclin D1 responded to altered
CXCR4 expression.
CXCR4 signaling differs in normal and cancer cells both at
the functional and molecular signaling levels. For example,
CXCL12 treatment of WT primary neonatal astrocytes induced
apoptosis, whereas it promoted enhanced survival in astrocy-
toma cultures (Warrington et al., 2007). In our study, CXCR4
suppression inhibited MPNST cell progression from G1 to S
phase in the cell cycle and resulted in potent inhibition of MPNST
cell growth in vitro and also in vivo tumor growth in several exper-
imental paradigms. MPNST cells with either chronic or acute
CXCR4 knockdown were deficient in allograft transplantations.ebruary 28, 2013 ª2013 Elsevier Inc. 1087
Administration of the CXCR4 inhibitor, AMD3100, also impeded
efficient tumor allotransplantation of murine MPNSTs. In
perhaps the most stringent assay, spontaneous MPNST devel-
opment was dramatically inhibited in a cisNf/p53 GEMM. This
result illustrates the potential power of spontaneous genetically
relevant malignant tumor mouse models as experimental tools
for cancer treatment discovery.
Our data point to a cell-autonomous pathway of activation but
do not rule out potential ligand contribution from other tumor-
associated sources. However, MPNST cells themselves provide
sufficient ligand to sustain autocrine cell growth in culture. We
make note that, although our CXCR4 shRNA experiments
provide similar allograft growth inhibition to that of AMD3100,
our studies do not address the possibility that pharmacological
inhibition of CXCR4 may extend to additional targets such as
bone-marrow-derived cells that may result in additional tumor
inhibitory effects.
CXCR4 Promotes MPNST Proliferation via PI3K and
GSK-3b
The function of theNF1 protein neurofibromin as a RAS-GTPase-
activating protein has traditionally focused attention on the
two main Ras effector pathways: raf/erk and PI3K/mTOR. Inhibi-
tion of the erk pathway can impact and even lead to reversal
of certain NF1 mutation-based phenotypes (Cui et al., 2008;
Wang et al., 2012). Other studies have reported that hyperactiva-
tion of the mTOR pathway underlies a growth advantage in NF1-
deficient MPNST cells and that rapamycin-mediated inhibition of
mTOR blunts MPNST growth in vivo (Johannessen et al., 2008;
Johansson et al., 2008). We saw modest downmodulation of
p-mTOR but saw no effects on p-S6 signaling in our SMPNST
system. In our study, NF1 loss specifically caused upregulation
of Akt/PI3Kinase, but not of Erk. By recent accounting, more
than 25 positive and negative effectors of Akt signaling have
been described (http://www.proteinLounge.com). How specific
pathways are selected for activity in a given cellular context
may depend in part on the AKT isoform, intracellular localization
of the active intermediates, and other factors not yet understood.
The association of CXCR4with various cancers has implicated
activation of several signaling effectors, including PLCg/Ca2+,
PI3K/AKT/NFkB, and Erk/p38, leading to chemotaxis, sur-
vival, angiogenesis, etc. (Balkwill, 2004). In MPNSTs, however,
CXCR4 depletion deactivated AKT, but not ERK or PLCg, thus
revealing cell context-specific pathway regulation. mTORC1
and GSK-3b are important downstream effectors of phospho-
AKT, and our results show that, in MPNSTs, CXCR4 depletion
more strongly impacts GSK-3b rather than mTOR through
PI3K and that GSK-3b mediates cyclin D1 expression. Thus,
we propose that the PI3K/GSK-3b branch downstream of
CXCR4 is sufficient to promote MPNST proliferation. These
studies, however, do not rule out that additional signaling path-
ways and effectors of AKT, b-catenin, and TCF may have
contributory functions in MPNST progression.
Soft tissue sarcomas are among the most therapy-resistant
and life-threatening forms of cancer. Our data indicate that
correction of abnormal CXCR4 signaling may be a promising
therapeutic target for NF1-associated MPNSTs. In addition, a
subset of sporadic MPNSTs may also co-opt this signaling1088 Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc.mechanism, in which case CXCR4 attenuation could poten-
tially benefit this patient population. Clinically-relevant CXCR4
inhibitors were initially developed for the treatment of HIV (Peled
et al., 2012). These include compounds of four different classes:
small-molecule inhibitors (e.g., AMD3100), small modified pep-
tides (e.g., BTK140), antibodies (e.g., ALX-0651), and modified
CXCL12 antagonists (e.g., CTCE-9908). Given the accumulating
evidence for the important role of this paracrine axis in cancer,
such compounds are currently being tested in early-phase clin-
ical trials (http://www.clinicaltrials.gov). Our preclinical observa-
tions supplemented by strong evidence that the CXCR4 axis
activity is sustained in human samples support the inclusion of
MPNST patients in such studies. Notably, effects of CXCR4
blockade are cytostatic rather than cytotoxic. However, taking
into account that surgery is the mainstay of MPNST treatment,
therapeutic approaches such as CXCR4 inhibition may improve
local growth control and enhance resectability. In addition,
sustained blockade of tumor development may provide an
opportunity for endogenous inflammatory and immune anti-
tumor responses to gain a foothold. Moreover, the identification
of additional pathways that can be targeted in combination with
CXCR4 will hopefully result in synthetic lethality and superior
anti-MPNST effects. Further studies will resolve this important
question.
EXPERIMENTAL PROCEDURES
All experimental procedures are described in detail in the Extended Experi-
mental Procedures.
MPNST Mouse Models
SKP MPNST Model
SKPs were isolated as previously reported (Le et al., 2009) from Nf1f/f;
p53f/f;Rosa26-LacZ mice. 105 NP/ SKPs were implanted subcutane-
ously into the same mouse from which the SKPs were originally isolated
(SMPNST autograft). The autologously transplanted SKPs gave rise to
MPNSTs within 2 months after implantation 100% of the time. The tumors ex-
hibited all the characteristics of human MPNST, including fascicular patterns
of tightly packed spindle cells with hyperchromatic nuclei and frequent
mitoses, as well as S100B expression (L.Q.L., T. Shipman, and L.F.P., unpub-
lished data).
SMPNST Allograft Model
SMPNST cells were subcutaneously injected into the backs of 5- to 6-week-
old athymic nude mice.
cisNP MPNST Model
A spontaneous endogenous GEMM for MPNSTs. We utilized amouse strain in
which null p53 and Nf1 alleles are configured in cis on the same chromosome
and spontaneously develop MPNST via loss of heterozygosity of both tumor
suppressor alleles (Vogel et al., 1999).
AMD3100 and Doxycycline Treatment In Vivo; Measurement of
Tumor Volume
AMD3100 Treatment of MPNST Allograft Model
MPNST cells were subcutaneously injected into the backs of 5- to 6-week-old
female athymic nude mice. The CXCR4 inhibitor AMD3100 was administered
subcutaneously daily at 5mg/kg of body weight, beginning at the time of tumor
detection.
AMD3100 Treatment of GEMM
AMD3100 (130 mg/d) or saline was administered using subcutaneously im-
planted osmotic minipumps (DURECT Corporation). Two month treatment
began when the mice were 16 weeks old.
Doxycycline was delivered in 5% sucrose-containing drinking water at
1 mg/ml. Tumor size was calculated by measuring length and width of the
lesion with the formula (length)3 (width)23 (0.52). All statistical analyses were
done with Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at http://dx.doi.org/10.
1016/j.cell.2013.01.053.
ACKNOWLEDGMENTS
We thank Karen Cichowski for the generous gift of the human MPNST
cell lines. This work was partially supported by funding from the National
Cancer Institute (grant R01 CA166593 to L.Q.L.), Department of Defense
(grant W81XWH-12-1-0161 to L.Q.L. and Postdoctoral Fellowship Award
grant W81XWH-11-1-0184 to W.M.), and the National Institutes of Health
(grant P50NS052606 to L.F.P.). L.Q.L. is a Disease-Oriented Clinical Scholar
and holds a Career Award for Medical Scientists from the BurroughsWellcome
Fund. L.F.P. is an American Cancer Society Research Professor.
Received: June 8, 2012
Revised: November 21, 2012
Accepted: January 30, 2013
Published: February 21, 2013
REFERENCES
Balkwill, F. (2004). The significance of cancer cell expression of the chemokine
receptor CXCR4. Semin. Cancer Biol. 14, 171–179.
Bertolini, F., Dell’Agnola, C., Mancuso, P., Rabascio, C., Burlini, A., Monestir-
oli, S., Gobbi, A., Pruneri, G., and Martinelli, G. (2002). CXCR4 neutralization,
a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Res. 62,
3106–3112.
Bian, X.W., Yang, S.X., Chen, J.H., Ping, Y.F., Zhou, X.D., Wang, Q.L., Jiang,
X.F., Gong, W., Xiao, H.L., Du, L.L., et al. (2007). Preferential expression of
chemokine receptor CXCR4 by highly malignant human gliomas and its
association with poor patient survival. Neurosurgery 61, 570–578, discussion
578–579.
Burger, J.A., Burger, M., and Kipps, T.J. (1999). Chronic lymphocytic leukemia
B cells express functional CXCR4 chemokine receptors that mediate
spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658–
3667.
Cichowski, K., Shih, T.S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin,
M.E., Bronson, R.T., and Jacks, T. (1999). Mouse models of tumor develop-
ment in neurofibromatosis type 1. Science 286, 2172–2176.
Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A.
(1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein
kinase B. Nature 378, 785–789.
Cui, Y., Costa, R.M., Murphy, G.G., Elgersma, Y., Zhu, Y., Gutmann, D.H., Par-
ada, L.F., Mody, I., and Silva, A.J. (2008). Neurofibromin regulation of ERK
signaling modulates GABA release and learning. Cell 135, 549–560.
Ferner, R.E. (2007). Neurofibromatosis 1. Eur. J. Hum. Genet. 15, 131–138.
Ghadimi, M.P., Young, E.D., Belousov, R., Zhang, Y., Lopez, G., Lusby, K., Kiv-
lin, C., Demicco, E.G., Creighton, C.J., Lazar, A.J., et al. (2012). Survivin is
a viable target for the treatment of malignant peripheral nerve sheath tumors.
Clin. Cancer Res. 18, 2545–2557.
Hoppler, S., and Kavanagh, C.L. (2007). Wnt signalling: variety at the core.
J. Cell Sci. 120, 385–393.
Johannessen, C.M., Johnson, B.W., Williams, S.M., Chan, A.W., Reczek, E.E.,
Lynch, R.C., Rioth, M.J., McClatchey, A., Ryeom, S., and Cichowski, K. (2008).
TORC1 is essential for NF1-associated malignancies. Curr. Biol. 18, 56–62.
Johansson, G., Mahller, Y.Y., Collins, M.H., Kim, M.O., Nobukuni, T., Perent-
esis, J., Cripe, T.P., Lane, H.A., Kozma, S.C., Thomas, G., and Ratner, N.
(2008). Effective in vivo targeting of the mammalian target of rapamycinpathway in malignant peripheral nerve sheath tumors. Mol. Cancer Ther. 7,
1237–1245.
Johnson, D.G., and Walker, C.L. (1999). Cyclins and cell cycle checkpoints.
Annu. Rev. Pharmacol. Toxicol. 39, 295–312.
Joseph, N.M., Mosher, J.T., Buchstaller, J., Snider, P., McKeever, P.E., Lim,
M., Conway, S.J., Parada, L.F., Zhu, Y., and Morrison, S.J. (2008). The loss
of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest
stem cells. Cancer Cell 13, 129–140.
Kijima, T., Maulik, G., Ma, P.C., Tibaldi, E.V., Turner, R.E., Rollins, B., Sattler,
M., Johnson, B.E., and Salgia, R. (2002). Regulation of cellular proliferation,
cytoskeletal function, and signal transduction through CXCR4 and c-Kit in
small cell lung cancer cells. Cancer Res. 62, 6304–6311.
Koshiba, T., Hosotani, R., Miyamoto, Y., Ida, J., Tsuji, S., Nakajima, S., Kawa-
guchi, M., Kobayashi, H., Doi, R., Hori, T., et al. (2000). Expression of stromal
cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer:
a possible role for tumor progression. Clin. Cancer Res. 6, 3530–3535.
Laverdiere, C., Hoang, B.H., Yang, R., Sowers, R., Qin, J., Meyers, P.A., Hu-
vos, A.G., Healey, J.H., and Gorlick, R. (2005). Messenger RNA expression
levels of CXCR4 correlate with metastatic behavior and outcome in patients
with osteosarcoma. Clin. Cancer Res. 11, 2561–2567.
Le, L.Q., and Parada, L.F. (2007). Tumor microenvironment and neurofibroma-
tosis type I: connecting the GAPs. Oncogene 26, 4609–4616.
Le, L.Q., Shipman, T., Burns, D.K., and Parada, L.F. (2009). Cell of origin and
microenvironment contribution for NF1-associated dermal neurofibromas.
Cell Stem Cell 4, 453–463.
Le, L.Q., Liu, C., Shipman, T., Chen, Z., Suter, U., and Parada, L.F. (2011).
Susceptible stages in Schwann cells for NF1-associated plexiform neurofi-
broma development. Cancer Res. 71, 4686–4695.
Lee, M.H., and Yang, H.Y. (2003). Regulators of G1 cyclin-dependent kinases
and cancers. Cancer Metastasis Rev. 22, 435–449.
Li, Y.M., Pan, Y.,Wei, Y., Cheng, X., Zhou, B.P., Tan, M., Zhou, X., Xia,W., Hor-
tobagyi, G.N., Yu, D., and Hung, M.C. (2004). Upregulation of CXCR4 is essen-
tial for HER2-mediated tumor metastasis. Cancer Cell 6, 459–469.
Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.H., Tan, Y., Zhang, Z., Lin, X., and
He, X. (2002). Control of beta-catenin phosphorylation/degradation by a dual-
kinase mechanism. Cell 108, 837–847.
Mantripragada, K.K., Spurlock, G., Kluwe, L., Chuzhanova, N., Ferner, R.E.,
Frayling, I.M., Dumanski, J.P., Guha, A., Mautner, V., and Upadhyaya, M.
(2008). High-resolution DNA copy number profiling of malignant peripheral
nerve sheath tumors using targeted microarray-based comparative genomic
hybridization. Clin. Cancer Res. 14, 1015–1024.
Mu¨ller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClana-
han, T., Murphy, E., Yuan, W., Wagner, S.N., et al. (2001). Involvement of che-
mokine receptors in breast cancer metastasis. Nature 410, 50–56.
Obaya, A.J., and Sedivy, J.M. (2002). Regulation of cyclin-Cdk activity in
mammalian cells. Cell. Mol. Life Sci. 59, 126–142.
Oh, J.W., Drabik, K., Kutsch, O., Choi, C., Tousson, A., and Benveniste, E.N.
(2001). CXC chemokine receptor 4 expression and function in human astro-
glioma cells. J. Immunol. 166, 2695–2704.
Peled, A., Wald, O., and Burger, J. (2012). Development of novel CXCR4-
based therapeutics. Expert Opin. Investig. Drugs 21, 341–353.
Righi, E., Kashiwagi, S., Yuan, J., Santosuosso, M., Leblanc, P., Ingraham, R.,
Forbes, B., Edelblute, B., Collette, B., Xing, D., et al. (2011). CXCL12/CXCR4
blockade induces multimodal antitumor effects that prolong survival in an
immunocompetent mouse model of ovarian cancer. Cancer Res. 71, 5522–
5534.
Rubin, J.B., and Gutmann, D.H. (2005). Neurofibromatosis type 1 - a model for
nervous system tumour formation? Nat. Rev. Cancer 5, 557–564.
Schrader, A.J., Lechner, O., Templin, M., Dittmar, K.E., Machtens, S., Mengel,
M., Probst-Kepper, M., Franzke, A., Wollensak, T., Gatzlaff, P., et al. (2002).
CXCR4/CXCL12 expression and signalling in kidney cancer. Br. J. Cancer
86, 1250–1256.Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc. 1089
Sehgal, A., Keener, C., Boynton, A.L., Warrick, J., and Murphy, G.P. (1998).
CXCR-4, a chemokine receptor, is overexpressed in and required for prolifer-
ation of glioblastoma tumor cells. J. Surg. Oncol. 69, 99–104.
Sengupta, R., Dubuc, A., Ward, S., Yang, L., Northcott, P., Woerner, B.M.,
Kroll, K., Luo, J., Taylor, M.D., Wechsler-Reya, R.J., and Rubin, J.B. (2012).
CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medul-
loblastoma. Cancer Res. 72, 122–132.
Serra, E., Rosenbaum, T., Winner, U., Aledo, R., Ars, E., Estivill, X., Lenard,
H.G., and La´zaro, C. (2000). Schwann cells harbor the somatic NF1 mutation
in neurofibromas: evidence of two different Schwann cell subpopulations.
Hum. Mol. Genet. 9, 3055–3064.
Sherr, C.J. (1995). D-type cyclins. Trends Biochem. Sci. 20, 187–190.
Singh, S., Singh, U.P., Grizzle, W.E., and Lillard, J.W., Jr. (2004). CXCL12-
CXCR4 interactions modulate prostate cancer cell migration, metalloprotei-
nase expression and invasion. Lab. Invest. 84, 1666–1676.
Srivastava, A.K., and Pandey, S.K. (1998). Potential mechanism(s) involved
in the regulation of glycogen synthesis by insulin. Mol. Cell. Biochem. 182,
135–141.
Taichman, R.S., Cooper, C., Keller, E.T., Pienta, K.J., Taichman, N.S., and
McCauley, L.K. (2002). Use of the stromal cell-derived factor-1/CXCR4
pathway in prostate cancer metastasis to bone. Cancer Res. 62, 1832–1837.
Tonsgard, J.H. (2006). Clinical manifestations and management of neurofibro-
matosis type 1. Semin. Pediatr. Neurol. 13, 2–7.
Vogel, K.S., Klesse, L.J., Velasco-Miguel, S., Meyers, K., Rushing, E.J., and
Parada, L.F. (1999). Mouse tumormodel for neurofibromatosis type 1. Science
286, 2176–2179.
Wang, Z., Ma, Q., Liu, Q., Yu, H., Zhao, L., Shen, S., and Yao, J. (2008).
Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression
in vitro via inactivation of canonicalWnt pathway. Br. J. Cancer 99, 1695–1703.1090 Cell 152, 1077–1090, February 28, 2013 ª2013 Elsevier Inc.Wang, Y., Kim, E., Wang, X., Novitch, B.G., Yoshikawa, K., Chang, L.S., and
Zhu, Y. (2012). ERK inhibition rescues defects in fate specification of Nf1-defi-
cient neural progenitors and brain abnormalities. Cell 150, 816–830.
Warrington, N.M., Woerner, B.M., Daginakatte, G.C., Dasgupta, B., Perry, A.,
Gutmann, D.H., and Rubin, J.B. (2007). Spatiotemporal differences in CXCL12
expression and cyclic AMP underlie the unique pattern of optic glioma growth
in neurofibromatosis type 1. Cancer Res. 67, 8588–8595.
Zeelenberg, I.S., Ruuls-Van Stalle, L., and Roos, E. (2003). The chemokine
receptor CXCR4 is required for outgrowth of colon carcinoma micrometasta-
ses. Cancer Res. 63, 3833–3839.
Zheng, H., Chang, L., Patel, N., Yang, J., Lowe, L., Burns, D.K., and Zhu, Y.
(2008). Induction of abnormal proliferation by nonmyelinating schwann cells
triggers neurofibroma formation. Cancer Cell 13, 117–128.
Zhou, Y., Larsen, P.H., Hao, C., and Yong, V.W. (2002). CXCR4 is a major che-
mokine receptor on glioma cells and mediates their survival. J. Biol. Chem.
277, 49481–49487.
Zhu, Y., and Parada, L.F. (2001). Neurofibromin, a tumor suppressor in the
nervous system. Exp. Cell Res. 264, 19–28.
Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K., and Parada, L.F. (2002). Neuro-
fibromas in NF1: Schwann cell origin and role of tumor environment. Science
296, 920–922.
Zou, C.Y., Smith, K.D., Zhu, Q.S., Liu, J., McCutcheon, I.E., Slopis, J.M.,
Meric-Bernstam, F., Peng, Z., Bornmann, W.G., Mills, G.B., et al. (2009).
Dual targeting of AKT and mammalian target of rapamycin: a potential thera-
peutic approach for malignant peripheral nerve sheath tumor. Mol. Cancer
Ther. 8, 1157–1168.
